SEC Tracker
Get the app

Alto Neuroscience ANRO

Alto Neuroscience reported a $25.12 million net loss

Alto Neuroscience (ANRO) filed a 10-Q with the SEC on Nov 10, 2026, 4:32 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Net loss of $25.12 million for the three months ended Sep 30, 2026
  2. Diluted EPS of -$0.54 for the three months ended Sep 30, 2026
  3. Cash and equivalents of $319.34 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Alto Neuroscience files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

2 new legal mentions

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Net income−$25.12M−$27.64M+9.1%
EPS−$0.54−$0.65+17%
Cash$319.34M$243.73M+31%
New legal mentions (2)
  • The Company filed a motion to dismiss the second amended complaint on May 5, 2026.
  • The Company filed a motion to dismiss the third amended complaint on September 11, 2026.

Data on this page was fetched . The filing on SEC.gov is the record.